OR WAIT 15 SECS
Agilent Technologies Inc. has announced that Dr. Lawrence J. Lesko from the University of Florida’s College of Pharmacy in Orlando, USA, has received an Agilent Thought Leader Award for his research into preclinical toxicological assessments of new medicines.
Agilent Technologies Inc. (Santa Clara, California, USA) has announced that Dr. Lawrence J. Lesko, of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s College of Pharmacy in Orlando, USA, has received an Agilent Thought Leader Award for his research into preclinical toxicological assessments of new medicines.
Dr. Lesko and his team are working to identify novel biomarkers that can help drug makers better assess new drug candidates and can also potentially enable doctors to better manage treatments.
Monty Benefiel, Agilent vice president and general manager of the Mass Spectrometry Division, said: “We are pleased to support Dr. Lesko’s research, which is addressing important needs in the rapidly evolving field of systems toxicology.”
“I am very pleased and appreciative of Agilent’s Thought Leader Award,” said Dr. Lesko. “It enables our team to identify metabolomic safety biomarkers of drug-induced renal toxicity and the mechanisms by which these toxicities occur. This research will lead us to identifying at-risk patients and exploring the use of concomitantly administered medicines as protectants against drug-induced renal damage. It could have a major effect on improving drug development and clinical care.”